CTAD 2024 Sessions & Poster Presentations
Learn about the latest study findings from Linus Health
Posters will be on display for in-person viewing on November 1, from 7:30 a.m. to 5:00 p.m. CET. All posters are also accessible anytime on the CTAD24 digital platform.
CLINICAL TRIALS: COGNITIVE AND FUNCTIONAL ENDPOINTS
Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning Enabled Digital Cognitive Assessment
Ali Jannati, MD, PhD
Director of Cognitive Science, Linus Health
Location: P171
Key takeaways:
- The Digital Clock and Recall (DCR) was non-inferior to blood-based biomarkers (BBMs) including pTau-217, Aβ42/40, and pTau-181 in predicting Aβ PET status cognitive impairment and superior or comparable to cognitive tests like MMSE, Cognivue, and RAVLT in classifying cognitive impairment.
- Combining the DCR with BBMs improved their Aβ-PET prediction performance, making it comparable to cerebrospinal fluid biomarkers.
- These results demonstrated that the DCR effectively streamline recruitment for AD clinical trials by accurately identifying cognitive impairment and predicting amyloid-beta (Aβ) PET status, thereby offering a cost-effective solution for selecting suitable participants for AD trials and reducing screen failure rates.
CLINICAL TRIALS: COGNITIVE AND FUNCTIONAL ENDPOINTS
Incorporating personally defined brain health priorities in clinical trials outcomes: the electronic Person Specific Outcome Measure approach in the US
Alvaro Pascual-Leone, MD, PhD
Chief Medical Officer, Linus Health
Department of Neurology, Harvard Medical School
Location: LP092
Key takeaways:
- The study demonstrates there is heterogeneity in individual-level brain health priorities in the US.
- The findings indicate that self-reported confidence in managing personally meaningful priorities may be an appropriate construct to incorporate the person’s voice in study outcomes. The findings of our study support the notion that treatments in ADRD should be developed with a person-centered approach.
- The ePSOM tool supports the establishment of clinical meaningfulness in AD trials and is now being validated in other global populations.
COGNITIVE ASSESSMENT AND CLINICAL TRIALS
Identification of Cognitive Impairment in Alzheimer’s Disease with Drawing and Speech-Based Assessments and Metrics
Tanya Talkar
Data Scientist, Linus Health
Location: P182
Key takeaways:
- The findings of our study showcase the benefits of combining speech- and linguistic-based metrics with drawing- and process-based metrics in screening for cognitive impairment.
- Both assessments used to derive metrics are brief and can be administered both in the clinic and remotely, allowing for easy, repeated recordings to screen for AD clinical trials or evaluation for DMTs.
DIGITAL HEALTH/E-TRIALS
Digital Assessment of Cognition for Optimizing Neuropsychology Workflow
Ali Jannati, MD, PhD
Director of Cognitive Science, Linus Health
Location: P231
Key takeaways:
- The study proposes a workflow involving a "Technology-enabled Psychometry Assistant" (TPA), a medical assistant equipped with the Linus Health Core Cognitive Evaluation (CCE) and Clinical Decision Support (CDS) system, to streamline the initial cognitive assessment process at the primary care level.
- A random forest model based on the CCE achieved a high level of accuracy (AUC = 0.887) in classifying cognitive impairment.
- The proposed workflow can significantly improve the efficiency of neuropsychological evaluations by reducing the workload of specialists, avoiding unnecessary referrals, and prioritizing those that need further assessment.
Curious about our solutions for clinical trials?
Take a closer look at our platform to learn more about the suite of digital assessments Linus offers.